National Institute of Child Health and Human Development, Contracts Management Branch, 6100 Bldg., Suite 7A07, 6100- Executive Blvd MSC 7510, Bethesda, MD 20892-7510

A -- CLINICAL TRIALS OF THE INHIBITOR OF HEME OXYGENASE, SN-MESOPORPHYRIN, IN THE MANAGEMENT OF NEONATAL HYPERBILIRUBINEMIA SOL NIH-NICHD-2000-15 POC Mya Nwe Hlaing, Contracting Officer, Contracts Management Branch, (301) 435-6958 WEB: National Institutes of Health, www.nih.gov. E-MAIL: mh89m@nih.gov, mh89m@nih.gov. The National Institute of Child Health and Human Development has a need to extend the current contract NO1-HD-5-3234 with The Rockefeller University, New York, using other than full and open competition to continue and add a new study in healthy term and near term infants to compare the efficacy of (tin mesoporphyrin {SnMP}) (6 umol/Kg BW) administered at pre-determined age specific bilirubin levels versus standard phototheraphy to control hyperbilirubinemia. In addition, short and long-term safety of this treatment will be determined in follow-up examinations. Studies to improve the course of neonatal hyperbilirubinemia have been and are ongoing with the Rockefeller University for five years. The purpose of this synopsis is to determine whether there are other sources that can perform the work described above without any interruptions to the ongoing project. Capability statements should be submitted within 45 days of the publication of this synopsis to Mrs. Mya N. Hlaing, Contracting Officer, CMB, NICHD, NIH, 6100 Executive Blvd., Suite 7A-07, MSC 7510, Bethesda, MD 20892-7510, telephone (301) 435-6958, FAX (301) 402-3676. (See Numbered Note 22) Posted 06/29/00 (W-SN469968). (0181)

Loren Data Corp. http://www.ld.com (SYN# 0016 20000703\A-0016.SOL)